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Objective:We conducted this study to test the hypothesis that plasma zonulin levels are
elevated in pediatric patients with nephrotic syndrome compared to healthy controls.
Study Design: Plasma zonulin levels were measured by ELISA in 114 children
enrolled in the NEPTUNE study. Clinical and laboratory data were retrieved from the
NEPTUNE database.
Results: The median age of the patients was 10 (IQR= 5 to 14) years, 59 were male, 64
had minimal change disease, 47 focal segmental glomerulosclerosis, median eGFR was
96 (IQR = 80 to 114) ml/min/1.73 m2, and median urine protein:creatinine ratio was 0.5
(IQR = 0.1 to 3.4) (g:g). The plasma zonulin level was 14.2 ± 5.0 vs. 10.2 ± 2.5 ng/ml
in healthy adults in a report using the same assay kit, P = 0.0025. These findings were
confirmed in an independent cohort of children with nephrotic syndrome compared to
healthy age-matched controls, P = 0.01. Zonulin concentrations did not differ in children
with minimal change disease vs. focal segmental glomerulosclerosis, frequently relapsing
vs. steroid-dependent vs. steroid-resistant clinical course, and were not influenced by
the immunosuppressive treatment regimen. There was no relationship between plasma
zonulin levels and the absolute or percentage change in proteinuria from enrollment until
the time of the zonulin assay.
Conclusion: Plasma zonulin levels are elevated in childhood nephrotic syndrome
regardless of level of proteinuria or specific treatment. The cause of the high plasma
zonulin levels and whether zonulin contributes to glomerular injury requires further study.
Keywords: nephrotic syndrome, minimal change disease, focal segmental glomerulosclerosis, zonulin, PAR-2
Trachtman et al. Plasma Zonulin and Nephrotic Syndrome
BACKGROUND
Primary nephrotic syndrome (NS) in childhood is a rare
condition with an annual incidence of 2–7/100,000 (1). It
is most commonly caused by either minimal change disease
(MCD) or focal segmental glomerulosclerosis (FSGS), which
are distinguished histologically and clinically by responsiveness
to treatment. The first line therapy for children with NS is
corticosteroids. Other immunosuppressive agents are used in
patients who are resistant to corticosteroids or who develop
serious side effects (2). Patients with MCD consistently achieve
remission of proteinuria when treated with corticosteroids or
other immunosuppressive medications and have an excellent
long-term prognosis with resolution of the disease and
preservation of kidney function. In contrast, nearly 50% children
with FSGS are resistant to currently available therapies and are
at high risk of progression to end stage kidney disease. MCD
likely results from a disturbance in the immune system. This
is based on recent genetic studies linking steroid responsive
NS to polymorphisms in the HLA-DQ and DR locus (3, 4).
In addition, the therapeutic response to corticosteroids and
agents that target T and B cells lends further support for a
role of the immune system in the pathogenesis of MCD (5).
FSGS is more heterogeneous and may reflect the presence of
a circulating permeability factor, a genetic abnormality in the
podocyte that leads to proteinuria, or other environmental or
infectious etiologies (6, 7). For both disease entities, there is a
pressing need to identify new approaches to treatment that are
safe and effective.
Case reports suggest that some children with NS are
responsive to dietary modifications (8). Lagrue reported two case
series in which, in the aggregate, more than half of children with
NS had a favorable response to a variety of dietary interventions
(9, 10). Two out of 3 children placed on a gluten-free diet (GFD)
had a complete remission. Uy et al. (11) outlined the potential
utility of gluten- and dairy-free diets in childhood NS. In a
recent retrospective study, 8 children with difficult-to-manage
NS benefited from placed on a GFD for 3.4 ± 4.3 years (range,
0.6–14 years). However, the literature detailing the response of
patients with NS to dietary interventions is limited and fairly old.
In addition, there is no description of renal histology or precise
delineation of the disease pattern. In a recent retrospective study,
there was a clinical benefit with a ≥50% reduction in annual
relapses rate in 7 children and a decreased number and dosage
of immunosuppressive medications prescribed in all cases (12).
In celiac disease, zonulin is released from enterocytes
after exposure to gliadin, activates protease-activated receptor
2 (PAR2) in a paracrine manner, and perturbs the actin
cytoskeleton and cell-cell junctions in the gut epithelium (13–16).
PAR2 is expressed on podocytes and a gluten-induced elevation
in the serum zonulin level may increase binding of the ligand to
the receptor. This in turn may modulate the interaction between
PAR2 and PAR3, which has been implicated in cell signaling
and podocyte structure and function (17–20). Alterations in the
podocyte cytoskeleton influence cell motility and attachment to
the glomerular basement membrane leading to proteinuria (21).
Furthermore, a zonulin knock-in mouse model with elevated
serum zonulin levels develops albuminuria (unpublished data).
Based on these clinical and pre-clinical findings, we conducted
this study to test the hypothesis that plasma zonulin levels are
elevated in pediatric patients with NS compared to published
estimates from healthy controls.
METHODS
Patients
The eligibility criteria and the clinical procedures of the
NEPTUNE multicenter, observational cohort study have been
published previously (see Appendix) (22). In brief, NEPTUNE,
which is part of the National Institutes of Health (NIH) Rare
Disease Clinical ResearchNetwork (RDCRN), has enrolled adults
and children withMCD, FSGS, and membranous nephropathy at
the time of clinically indicated renal biopsy. Initial visits include
an extensive clinical history, physical examination, collection
of urine, blood and renal tissue samples, and assessments of
quality of life and patient-reported outcomes. Follow-up history,
physical measures, urine and blood samples, and questionnaires
are obtained every 4 months in the first year and biannually,
thereafter. Samples (urine, serum, plasma, and DNA) are
stored in a biorepository and available for use in approved
ancillary studies.
The following clinical and laboratory data were collected
in accord with the approved NEPTUNE ancillary study
protocol: age, gender, race/ethnicity, disease group, treatment,
blood pressure (BP), estimated glomerular filtration rate
(eGFR), quantitative proteinuria, and serum albumin and
cholesterol concentrations.
A validation cohort of children with NS treated at NYU
Langone Health who were not enrolled in NEPTUNE was
recruited for measurement of plasma zonulin level concurrently
with samples collected from healthy age-matched control
children who were enrolled in an independent NIH sponsored
observational cohort study, C-PROBE. The C-PROBE cohort
study is an observational cohort and biobanking study of patients
with chronic kidney disease and healthy controls (23).
Samples and Analytical Methods
Plasma specimens collected from all patients ≤18 year old with
MCD or FSGS enrolled in the NEPTUNE study were tested
for plasma zonulin concentration. Most of the samples were
available for testing from the 4 (n = 86) or 8 month (n = 19)
protocol visit with the remaining 9 samples collected at the 12–
30 month visits. The selection of the visit for which a sample
was retrieved for zonulin measurement was determined by
availability of specimens in theNEPTUNE biorepository. Clinical
and laboratory data were retrieved coincident with the visit when
the zonulin level was measured. Plasma zonulin levels were
measured in the NYU Core Laboratory using a commercially
available ELISA kit (Immunodiagnostik AG).
Statistical Methods
Descriptive summaries are provided for the final sample of
subjects with zonulin measurements. Continuous data are
summarized as medians and interquartile ranges and with
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TABLE 1 | Clinical and laboratory features of the study sample by elevated zonulin level (n = 114).
All Patients Normal Zonulin
(≤15.2 ng/ml)
Elevated Zonulin
(>15.2ng/ml)
p
n = 114 n = 60 n = 54
Age (year), median (IQR) 10 (5, 14) 11 (5, 14) 9 (5, 14) 0.72
0–6, n (%) 2 (2) 2 (3) 0 (0)
7–12, n (%) 41 (36) 20 (33) 21 (39)
13–17, n (%) 32 (28) 15 (25) 17 (31)
Unknown, n (%) 39 (34) 23 (38) 16 (30)
Gender 0.05
Male, n (%) 59 (52) 36 (60) 23 (43)
Female, n (%) 53 (46) 22 (27) 31 (57)
Unknown, n (%) 2 (2) 2 (3) 0 (0)
Race 0.18
Multi-racial, n (%) 9 (8) 4 (7) 5 (9)
Asian/Asian American, n (%) 10 (9) 3 (5) 7 (13)
Black/African American, n (%) 44 (39) 20 (33) 24 (44)
White/Caucasian, n (%) 45 (39) 29 (48) 16 (30)
Unknown, n (%) 6 (6) 4 (7) 2 (4)
Diagnosis 0.41
MCD, n (%) 64 (56) 32 (53) 32 (59)
FSGS, n (%) 47 (41) 25 (42) 22 (41)
Non-biopsied, n (%) 2 (1) 2 (3) 0 (0)
Other, n (%) 1 (1) 1 (2) 0 (0)
Clinical disease activity 0.57
IRNS, n (%) 27 (24) 12 (20) 15 (28)
FRNS/SDNS, n (%) 41 (36) 25 (42) 16 (30)
SRNS, n (%) 30 (26) 15 (25) 15 (28)
Unknown, n (%) 16 (14) 8 (13) 8 (15)
SBP %tile, Median (IQR) 71 (46, 91) 71 (47, 95) 69 (42, 89) 0.65
DBP %tile, Median (IQR) 73 (43, 88) 70 (39, 87) 73 (46, 89) 0.63
Urine protein: creatinine ratio
(g/g) at screening, Mean (SD)
4.8 (1.8, 9.6) 4.9 (2.2, 10.6) 4.6 (1.2, 9.2) 0.55
Urine protein: creatinine ratio(g/g)
at baseline visit, Median (IQR)
1.4 (0.2, 5.3) 2.7 (0.3, 5.7) 0.8 (0.1, 4.7) 0.11
Urine protein: creatinine ratio(g/g)
at visit with zonulin
measurement, Median (IQR)
0.5 (0.1, 3.4) 0.7 (0.2, 5.5) 0.4 (0.1, 1.4) 0.04
eGFR (mL/min/1.73 m2) at
zonulin assessment, Median
(IQR)
96 (80, 114) 96 (76, 115) 97 (80, 113) 0.98
Serum albumin (mg/dL) at
zonulin assessment, Median
(IQR)
3.5 (2.7, 4.2) 3.2 (2.4, 4.0) 3.8 (3.2, 4.3) 0.06
Cholesterol (mg/dL) at zonulin
assessment, Median (IQR)
198 (163, 289) 216 (166, 339) 192 (162, 261) 0.30
boxplots to display the distributions. Categorical data are
summarized as frequencies and percentages. Associations
between Zonulin levels and continuous variables, such as
proteinuria and eGFR, were evaluated using Spearman
non-parametric correlation coefficients. Zonulin levels were
compared across levels of categorical variables, such as diagnosis,
using Kruskal-Wallis non-parametric analysis of variance tests.
Zonulin levels were also compared to the healthy reference
population values with mean = 10.2 and SD = 2.5 using a
one-sample t-test (24). P-values < 0.05, 2-sided were considered
statistically significant. No adjustments were incorporated for
multiple testing. All analyses were completed using SAS V9.4
and R.
RESULTS
The clinical and laboratory features of the study patients at
baseline are summarized in Table 1. The median age was 10
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(IQR = 5–14) years old and the majority of patients were male.
The distribution of disease activity was almost evenly divided
between infrequently relapsing, frequently relapsing/steroid
dependent, and steroid resistant. Sixty-four children had MCD
and 47 had FSGS. The median blood pressure and level of kidney
function were normal. By design, urinary protein excretion was
elevated at enrollment into NEPTUNE. Clinically significant
nephrotic-range proteinuria (urine protein:creatinine ratio >2
g:g) and hypercholesterolemia (cholesterol concentration >170
mg/dl) were present in nearly a third of patients at baseline.
The mean plasma zonulin level in the total cohort of children
with NS was significantly elevated compared to healthy adults
in whom the circulating concentration was measured with the
same assay kit (24). There are few published data on plasma
zonulin levels in healthy children and adolescents but the mean
concentration in the NEPTUNE participants exceeded the value
in the limited sample of children of comparable age (25). Of note,
27% of the patients with NS had a plasma zonulin concentration
above 17.5 ng/ml, >3 SD above the mean value in adult controls.
To validate the findings in the NEPTUNE participants, we
measured plasma zonulin levels in an independent cohort of
children with NS treated at NYU Langone Health (n = 18)
and compared them to a group of healthy age-matched children
(n = 15) who were enrolled in the CPROBE cohort study. In
the controls, the median age was 14 (IQR = 12 to 17), 9 were
female, 3 were Hispanic ethnicity, and 4 were Black/African
American, 10 White/Caucasian and 1 chose not to report race.
The plasma zonulin levels were 18.6 ± 4.2 vs. 15.2 ± 2.7 ng/ml
in the children with NS and healthy controls, respectively,
P < 0.02. The difference is comparable to that observed in the
NEPTUNE patients and the values reported in the literature for
healthy children.
There were no differences in mean plasma zonulin levels
in patients with MCD 14.3 vs. FSGS 14.2 ng/ml (Figure 1).
Moreover, there was no difference in plasma zonulin level
when the patients were categorized by clinical disease activity—
frequently relapsing/steroid dependent, infrequently relapse, and
steroid resistant (Figure 2). Forty-eight percent of children
were on immunosuppressive treatment at enrollment and this
percentage increased to 67% at the time of sample collection
for zonulin determination. The plasma zonulin levels did not
differ in those not receiving immunosuppressive medication,
on corticosteroids alone, or on corticosteroids plus another
immunosuppressive medication (Figure 3).
The median urine protein:creatinine ratio at the visit when
plasma zonulin was 0.5 (IQR: 0.1 to 3.4}. There was no
correlation between plasma zonulin concentration and the level
at proteinuria at baseline or the next two visits including the
visit when the plasma zonulin level was measured (Figure 4)
nor between zonulin and eGFR on the day of the visit when
the plasma zonulin level was determined (Figure 5). There was
no association between plasma zonulin levels and absolute or
percentage change in proteinuria (data not shown). In an effort
to determine if there was a relationship between plasma zonulin
levels and the time to the next remission, we examined 61
patients who were not in a complete remission and who had
had subsequent follow-up data. In this subgroup of patients, the
FIGURE 1 | The box plots illustrate the mean, 25th and 75th percentiles, and
2SD boundaries of the plasma zonulin levels in children with MCD (n = 64) vs.
FSGS (47). The dashed line indicates-the mean+2SD plasma zonulin level in
healthy adult control participants. One sample t-test of MCD vs. healthy
controls (mean = 10.2; SD = 2.5): p < 0.001. One sample t-test of FSGS vs.
healthy controls (mean = 10.2; SD = 2.5): p < 0.001. SD, Standard deviation;
MCD, minimal change disease; FSGS, focal segmental glomerulosclerosis.
FIGURE 2 | The box plots illustrate the mean, 25th and 75th percentiles, and
2SD boundaries of the plasma zonulin levels in children with IRNS/SSNS
(n = 27) vs. FRNS/SDNS (n = 41) vs. SRNS (n = 30). The dashed line
indicates-the mean+2SD plasma zonulin level in healthy adult control
participants. One sample t-test of IRNS/Steroid sensitive vs. healthy controls
(mean = 10.2; SD = 2.5): p < 0.001. One sample t-test of FRNS/SDNS vs.
healthy controls (mean = 10.2; SD = 2.5): p < 0.001. One sample t-test of
SRNS vs. healthy controls (mean = 10.2; SD = 2.5): p < 0.001. SD, Standard
deviation; IRNS, infrequently relapsing nephrotic syndrome; FRNS, frequently
relapsing nephrotic syndrome; SDNS, steroid dependent nephrotic syndrome;
SRNS, steroid resistant nephrotic syndrome.
median follow-up was 41 months (IQR: 28 to 49). There were
37 patients who subsequently reached a complete remission and
the median time to achieve remission was 21 months. Zonulin
was not associated with time to remission (P = 0.27), regardless
of whether the analysis was performed based on untransformed,
transformed, or categorized plasma zonulin levels.
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FIGURE 3 | The box plots illustrate the mean, 25th and 75th percentiles, and
2SD boundaries of the plasma zonulin levels in children on no
immunosuppressive medications (n = 43) vs. steroids alone (n = 20) vs.
Steroids plus another immunosuppressive medication (n = 51) The dashed
line indicates-the mean+2SD plasma zonulin level in healthy adult control
participants. One sample t-test of No immunosuppressive medications vs.
healthy controls (mean = 10.2; SD = 2.5): p < 0.001. One sample t-test of
Steroids alone vs. healthy controls (mean = 10.2; SD = 2.5): p = 0.06. One
sample t-test of Steroids + Any other IST vs. healthy controls (mean = 10.2;
SD = 2.5): p < 0.001. SD, Standard deviation; IST, immunosuppressive
therapy.
FIGURE 4 | The scatterplot illustrates the relationship between plasma zonulin
level and the urine protein:creatinine ratio at the time of the zonulin
measurement. The dashed line indicates-the mean+2SD plasma zonulin level
in healthy adult control participants. Spearman’s Rho = −0.10, p = 0.33,
R2 = 0.01. SD, Standard deviation.
When the patients were divided into two groups, one with
nephrotic-range proteinuria and the other with sub-nephrotic
range proteinuria, there was a trend toward a higher plasma
zonulin level in the latter group (urine protein: creatinine
ratio < 2 g:g, n= 72) whose median zonulin level was 16.3 ng/ml
[interquartile range = 10.5–18.9] compared to the former group
of 31 patients with urine protein: creatinine ratio ≥2 g:g whose
median zonulin concentration was 11.6 ng/ml [interquartile
range = 9.0–16.6] (P = 0.08). The mean plasma zonulin level in
both subgroups was higher than the concentration reported in
healthy controls and the mean values were more similar between
subgroups (mean of 14.8 in urine protein:creatinine ratio ≥2 g:g
vs. mean of 13.1 in urine protein:creatinine ratio <2 g:g vs. mean
of 10.2 in healthy controls).
Although there was no correlation between plasma zonulin
level and blood pressure or serum cholesterol level, there was
a direct relationship with the serum albumin level (r = 0.24,
P = 0.04). Among most routinely available laboratory tests
(proteinuria, eGFR or cholesterol concentration), there were no
significant predictors of an elevated plasma zonulin level.
DISCUSSION
In this study, we demonstrate that plasma zonulin levels are
elevated in pediatric patients with NS regardless of level of
proteinuria or specific therapy. This finding, based on analysis
of samples collected in patients enrolled in NEPTUNE was
confirmed in a validation cohort of children with NS in whom
plasma zonulin level was measured concurrently with a group
of healthy age-matched pediatric controls. Plasma zonulin levels
correlate with serum albumin level and are numerically higher in
those with sub-nephrotic range vs. nephrotic-range proteinuria.
There were no clinical or laboratory values that were significant
predictors of the plasma zonulin concentration. In a recent study
by Lukaszyk et al. (26), plasma zonulin levels were lower in
patients with early stage CKD compared to healthy adults, a
finding that may account for the lower plasma levels in the
children with nephrotic vs. sub-nephrotic proteinuria in the
NEPTUNE cohort. The cause of the high plasma zonulin level in
children with NS and how it may act on the podocyte to increase
proteinuria requires further study.
There are no established normative values for plasma zonulin
levels in children and most studies, like ours, compare the
concentration in a target population with the level in healthy
controls. Plasma zonulin levels, generally measured with the
commercial ELISA kit used in this study, have been demonstrated
to be higher in patients with celiac disease (27), sepsis (28),
and polycystic ovary syndrome (29) but similar in children with
autism compared to age-matched healthy controls (25). The latter
study showed an inverse relationship between age and plasma
zonulin levels. However, the plasma zonulin levels documented
in the NEPTUNE cohort of children with NS exceeded the mean
circulating concentration measured in all of these prior studies
including children of comparable age in the autism study (25).
Two studies have reported substantially higher plasma zonulin
levels in healthy adults and those with obesity, hyperlipidemia
and various gastrointestinal disorders excluding celiac disease
compared to the other reports and the current patient series
(26, 30). This discrepancy may relate to different procedures for
sample collection and/or processing and the inherent variability
in plasma zonulin levels based on a single determination (27).
The strength of this study is the fully phenotyped cohort. The
NEPTUNE study represents one of the largest well-characterized
groups of pediatric patients with NS secondary to MCD or
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FIGURE 5 | The scatterplot illustrates the relationship between plasma zonulin level and the urine protein:creatinine ratio at the time of the zonulin measurement. The
dashed line indicates-the mean+2SD plasma zonulin level in healthy adult control participants. Rho = 0.083 p = 0.76, R2 < 0.01. eGFR, estimated glomerular
filtration rate; SD, Standard deviation.
FSGS (21). Nonetheless, we acknowledge that sample size may
still be limited to detect differences in zonulin concentration in
patient subgroups based on specific clinical features or response
to treatment(s). True baseline samples prior to treatment were
not routinely available. In addition, samples were retrieved
for zonulin assay at different time intervals from baseline.
The vast majority of the specimens were collected at 4 (75%)
and 8 (17%) months with only 8% obtained at later time
points. The NEPTUNE protocol did not mandate therapy.
Patients received usual clinical management prescribed by their
clinical nephrologist during NEPTUNE participation and sample
acquisition. However, because treatment was not standardized
we cannot associate changes in plasma zonulin levels with
specific interventions. In addition, the measurement of plasma
zonulin levels was done before delineation of the steroid response
pattern which might have led to misclassification of this clinical
feature. Based on clinical practice in pediatric nephrology,
most children are treated with a variety of immunosuppressive
medications prior to a kidney biopsy, which was a requirement
for enrollment in NEPTUNE. In this cohort, 48% of children
were on immunosuppressive drugs at entry into NEPTUNE.
Thus, it is unlikely that analysis of baseline samples at entry into
NEPTUNE would addmore information. However, this question
can be readdressed in the ongoing CNEPTUNE cohort study
in which pediatric patients are enrolled within 30 days of the
onset of nephrotic syndrome. Treatment was not standardized
and we did not collect serial samples to assess changes in plasma
zonulin concentration over time or response to therapeutic
interventions. However, the comparable zonulin levels in the
patient subgroups on different treatment regimens suggest that
the abnormal zonulin levels are intrinsic to the glomerular disease
process. The NEPTUNE samples were not analyzed concurrently
with a group of healthy controls and comparison was made with
published values for plasma concentration in healthy subjects.
However, in a follow-up validation study, we confirmed that
plasma zonulin levels were higher in an independent cohort
of children with NS compared to age-matched healthy controls
from the CPROBE study with single batch analysis of all samples.
Zonulin is a relatively large molecule (molecular weight 47
kD) and it is not freely filtered in healthy children. The precise
pathophysiological cause for the increased plasma zonulin levels
in children with nephrotic syndrome (altered renal handling,
synthesis, or extra-renal clearance) requires further study.
Absent a straightforward correlation between plasma zonulin
levels and proteinuria, could this molecule and exposure to
gluten still be a contributing factor in the pathogenesis childhood
NS? In a recent study by Bouziat et al. (31), it was noted
that at most 2–5% of patients with HLA susceptibility alleles
who are exposed to gliadin develop celiac disease. To address
this quandary, in an experimental model of celiac disease, the
investigators demonstrated that exposure to reoviruses alters
the immune system toward a Th1 phenotype and promotes
the production of anti-gliadin antibodies and gastrointestinal
inflammation. Patients with celiac disease have higher titers of
antibodies to reovirus than controls that trend downward when
they are placed on a gluten-free diet. Many studies have explored
the role of viral infections in the pathogenesis of childhood NS.
In light of the linkage between a gluten-free diet and NS disease
activity, further investigation is warranted to test the hypothesis
that reovirus infection or other components of the microbiome
may be a second hit that modulates the immune system and
triggers nephrotic syndrome in select patients with high zonulin
levels. Additional clinical trials are needed to assess the potential
efficacy of a gluten-free diet in the management of children with
NS and to clarify the mechanism of action for this intervention.
CONCLUSION
The plasma zonulin level is elevated in childhood nephrotic
syndrome but it is not an indicator of disease activity. A pilot
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clinical trial is underway to determine if the plasma zonulin
level can be used as a biomarker of a favorable response to a
gluten-free diet.
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